According to the previous study (Loibl & Gianni, 2017), pertuzumab plus trastuzumab has been shown to achieve a complete pathological response on a higher proportion of patients than trastuzumab alone, demonstrating the success of adjuvant and neoadjuvant therapy in HER2-positive early breast cancer. Here, ERBB2 is linked to breast carcinoma.